Literature DB >> 10517787

A model of extravascular bubble evolution: effect of changes in breathing gas composition.

J F Himm1, L D Homer.   

Abstract

Observations of bubble evolution in rats after decompression from air dives (O. Hyldegaard and J. Madsen. Undersea Biomed. Res. 16: 185-193, 1989; O. Hyldegaard and J. Madsen. Undersea Hyperbaric Med. 21: 413-424, 1994; O. Hyldegaard, M. Moller, and J. Madsen. Undersea Biomed. Res. 18: 361-371, 1991) suggest that bubbles may resolve more safely when the breathing gas is a heliox mixture than when it is pure O(2). This is due to a transient period of bubble growth seen during switches to O(2) breathing. In an attempt to understand these experimental results, we have developed a multigas-multipressure mathematical model of bubble evolution, which consists of a bubble in a well-stirred liquid. The liquid exchanges gas with the bubble via diffusion, and the exchange between liquid and blood is described by a single-exponential time constant for each inert gas. The model indicates that bubbles resolve most rapidly in spinal tissue, in adipose tissue, and in aqueous tissues when the breathing gas is switched to O(2) after surfacing. In addition, the model suggests that switching to heliox breathing may prolong the existence of the bubble relative to breathing air for bubbles in spinal and adipose tissues. Some possible explanations for the discrepancy between model and experiment are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517787     DOI: 10.1152/jappl.1999.87.4.1521

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  2 in total

Review 1.  Kinetic and dynamic models of diving gases in decompression sickness prevention.

Authors:  Robert Ball; Sorell L Schwartz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Hyperventilation impairs brain function in acute cerebral air embolism in pigs.

Authors:  Robert A van Hulst; Jack J Haitsma; Thomas W Lameris; Jan Klein; Burkhard Lachmann
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.